SmallCapStockAnalyst.com Announces (OTCBB: GXPI) Price Target $1.38

Stocks to Watch: Gemini Explorations, Inc.  (OTCBB: GXPI), Oxford Investments Holdings Inc. (OTC BB:OXIHF) ,PARI Pharma (NasdaqGS:GILD) , Applied DNA Sciences, Inc. (OTC BB:APDN) , MIV Therapeutics Inc. (OTC BB:MIVT)

Featured Stock: Gemini Explorations, Inc.

(OTCBB: GXPI)

Current Price (0.16)

www.SmallCapStockAnalyst.com

Updated Gemini Explorations Report Discusses Increased Cash Flow Projections

from IPOdesktop.com

Los Angeles, CA -- November 27, 2007 Gemini Explorations (GXPI.OB) Analyst Report Update discussing increased cash flow projections from gold projects in Columbia, is available from IPOdesktop.com.

Gemini Explorations is a junior resource company exploring and developing gold properties in southern Columbia

REPORT LINK

IPOdesktop research report

http://www.gaskinsco.com/linkto-gxpi-nov.shtml

About Gemini Explorations

http://www.geminiexploration.com/index.html

Gemini Explorations completed the purchased of 80 percent controlling interest in the Los Chorros mine and has secured first rights of refusal on the remaining 20 percent interest with 18 months.  The company has received an equipment grant from the Columbian Government to assist in the modernization and re-development of the Los Chorros Mine. The first shipment of equipment arrived at the property in the first week of September 2007 and will further expedite the modernization and re-development of the Los Chorros Mine. . Gemini’s newly acquired La Planada property is located in the municipality of Sotomayor, department of the Nariño, in southwestern Colombia, and a drilling program has been set.

About IPOdesktop

http://IPOdesktop.com

IPOdesktop.com, the leading provider of independent IPO research for professional money managers and individual investors, also produces the IPO Hardball radio program.

In the 'Analysts Corner' at IPOdesktop.com, research reports are available for both recent IPOs and emerging companies.

http://gaskinsco.com/linkto-analysts-corner.htm

IPOdesktop editors are quoted by The Wall Street Journal, Dow Jones Newswires, MarketWatch, Reuters, USATODAY, and others. IPOdesktop editors also co-host financial programs at StreetIQ.com.

Disclaimer

IPOdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this analyst report report, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made.

DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. ID has been paid up to eighty five hundred dollars from equityallianceir for preparation and posting of this report and other advertising services. This constitutes a conflict of interest as to ID’s ability to remain objective in its communication regarding the subject company…more safe harbor & disclaimer

http://gaskinsco.com/report-disclaimer-c.htm

Contact:

Michael Hill

     President

     Gemini Explorations, Inc

     8th Floor, 5201 Blue Lagoon Drive

     Miami, Florida 33126

           http://www.geminiexploration.com

     email: info@geminiexploration.com

     IR info: 1 877 700 1644

For an in-depth analyst report, please visit: www.SmallCapStockAnalyst.com

Oxford Investments Holdings Inc.

(OTC BB:OXIHF)

Current Price (0.12)

www.SmallCapStockAnalyst.com

TORONTO, ONTARIO---Nov 26, 2007 -- Oxford Investments Holdings Inc. (OTC BB:OXIHF.OB - News) is pleased to announce that its Wanzhi Electron Joint Venture Foshan Foshantong Information Technology Co., Ltd. (Foshantong), through a strategic investment, has acquired controlling interest in Foshan Jiaxun Information Technology Co., Ltd. Jiaxun specializes in office equipment sales, service, repair and maintenance. Its service centers provide support for most major electronics manufacturers. Jiaxun also provides systems integration and software implementation services through its consulting practice and the infusion of capital will enable Jiaxun to aggressively bid on more consulting contracts. As a result of the Foshantong investment, Jiaxun has expanded its operations into the consumer sector by opening four office supply retail stores in the districts of Guicheng, Lishui, Luocun and Shishan. These outlets will also provide marketing, sales and support of the Foshantong and Education-One electronic payments card programs administered by Wanzhi.                  Oxford Investments Holdings Inc. is now establishing itself as a leading online payment solutions Company. The Company is concentrating its business around its "FocusKard" suite of products. The FocusKard suite provides a comprehensive card payment solution meshed with a user-friendly e-wallet for e-commerce businesses.

     

PARI Pharma

(NasdaqGS:GILD)

Current Price (41.91)

www.SmallCapStockAnalyst.com

MONTEREY, Calif., Nov. 26 -- PARI Pharma's eFlow electronic nebulizer was included in Gilead's (Nasdaq: GILD - News) recent New Drug Application (NDA) submittal to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily). Aztreonam lysine for inhalation, delivered by eFlow, is an investigational therapy in development for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.                     PARI Pharma focuses on the development of aerosol delivery devices and therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Applied DNA Sciences, Inc.

(OTC BB:APDN)

Current Price (0.12)

www.SmallCapStockAnalyst.com

STONY BROOK, N.Y.--Nov 26--Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN - News), a provider of DNA-based security solutions, today announced that it has shipped its first commercial order of DermalRx™. DermalRx is an ingredient that acts as an alternative to chemical peels in a new skin care product that is being manufactured under a top selling label of a large multinational company. This product is expected to be launched in Spring 2008.        Applied DNA Sciences, Inc. provides botanical DNA encryption, embedment and authentication solutions that can help protect companies, governments and consumers from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion into physical locations and databases. APDN’s common stock is listed on the Over-The-Counter Bulletin Board under the symbol "APDN."

MIV Therapeutics Inc.

(OTC BB:MIVT)

Current Price (0.43)

www.SmallCapStockAnalyst.com

ATLANTA, GA---Nov 26, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that Dr. Mark Landy, president of MIV Therapeutics, will present a company overview at the BMO Capital Markets Focus On Healthcare Conference on December 4, 2007 at 2:30 p.m. Eastern Time. The conference will be held at Millennium Broadway Hotel in New York City on December 4th and 5th.                    MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

SmallCapStockAnalyst.com is owned and operated by Iron Consulting.

Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapStockAnalyst.com is owned and operated by Iron Consulting. Iron Consulting has received seventy one thousand dollars from Equity Alliance Intl. LLC www.equityallianceir.com for a two month internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Market Advisors Inc.

The information and opinions in this report were prepared by Market Advisors Inc. (located in Nebraska) who does receive fees for services including preparation of this report. For this report, officers of Market Advisors Inc received $2,500 from a non-affiliated third party. This is not an offer to buy or sell securities nor should this report be construed as investment advise. Information or statements are subject to numerous risks and uncertainties that cause such statements not to prove accurate. Market Advisors, Inc. does not disseminate, nor is it liable for the dissemination by any third party of this information.